News
AVTX
0.1192
+16.29%
0.0167
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 1d ago
CETX, MYO and MORF among mid-day movers
Seeking Alpha · 1d ago
What's Going On With Avalo Therapeutics (AVTX) Stock?
Benzinga · 1d ago
Nasdaq Rises 50 Points; US Manufacturing PMI Improves In September
Benzinga · 1d ago
VolitionRx, Avalo Therapeutic among healthcare movers
Seeking Alpha · 1d ago
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
Weekly Report: what happened at AVTX last week (0911-0915)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/15 17:31
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 09/15 16:40
Dow Dips 100 Points; US Export Prices Rise 1.3% In August
Benzinga · 09/15 14:58
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/15 13:06
Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/15 11:54
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investorplace · 09/15 11:33
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/14 21:31
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 09/14 16:58
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/14 13:06
More
Webull provides a variety of real-time AVTX stock news. You can receive the latest news about Avalo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).